Mantelli M I, Roques B B, Blanchard T A, Mounier M, Quincey M, Jolivet F B, Jousserand N P, Marchand A, Diquélou A N, Reynolds B S, Coyne M, Trumel C, Lefebvre H P, Concordet D, Lavoué R
Department of Clinical Sciences, Université de Toulouse, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France.
Department of Physiology & Therapeutics, Université de Toulouse, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France.
Am J Vet Res. 2022 Feb 16;83(5):434-442. doi: 10.2460/ajvr.21.09.0150.
To investigate the effects and duration of orally administered prednisolone on renal function evaluated by glomerular filtration rate (GFR) determination and creatinine (Cr) and symmetric dimethylarginine (SDMA) concentrations as well as on urinalysis, electrolytes, and hydric status in healthy dogs.
14 healthy Beagles.
In this prospective double-masked placebo-controlled study, dogs were randomized after baseline evaluation to receive a 7-day course of either prednisolone (1.5 to 2.0 mg/kg, PO, q 12 h) or a placebo. A repeated-measure design was performed, each dog participating in 4 successive sampling sessions. Clinical data, systolic blood pressure, CBC, and biochemical analyses including serum SDMA concentration, GFR determination, urine output quantification, and complete urinalysis were performed for all dogs the day before (D0) and at the end of steroid administration (D7) as well as 2 weeks (D21) and 4 weeks (D35) after the end of treatment.
At D7, when compared with baseline, GFR increased significantly in treated dogs, whereas creatinine and SDMA concentrations decreased significantly. GFR and Cr but not SDMA modifications persisted significantly at D21. None of the variables differed significantly from baseline at D35. The OR of presenting an albumin band on urine electrophoresis was 2.4 times as high in treated versus control dogs (OR, 36; 95% CI, 1.8 to 719.4; P = 0.02).
A short-term course of immune-suppressive prednisolone treatment in healthy dogs leads to a sustained but reversible renal hyperfiltration state. Modification in electrolytic variables can affect the clinical interpretation of blood work in such patients.
通过测定肾小球滤过率（GFR）、肌酐（Cr）和对称二甲基精氨酸（SDMA）浓度来评估口服泼尼松龙对健康犬肾功能的影响及持续时间，同时观察其对尿液分析、电解质和水合状态的影响。
14只健康比格犬。
在这项前瞻性双盲安慰剂对照研究中，犬只在基线评估后随机分组，接受为期7天的泼尼松龙（1.5至2.0毫克/千克，口服，每12小时一次）或安慰剂治疗。采用重复测量设计，每只犬参与4次连续采样。在治疗前一天（D0）、类固醇给药结束时（D7）以及治疗结束后2周（D21）和4周（D35），对所有犬只进行临床数据、收缩压、全血细胞计数以及包括血清SDMA浓度、GFR测定、尿量定量和完整尿液分析在内的生化分析。
在D7时，与基线相比，治疗组犬只的GFR显著升高，而肌酐和SDMA浓度显著降低。在D21时，GFR和Cr的变化仍显著持续，但SDMA无显著变化。在D35时，所有变量与基线相比均无显著差异。治疗组犬只尿液电泳出现白蛋白条带的比值比对照组高2.4倍（比值比，36；95%置信区间，1.8至719.4；P = 0.02）。
健康犬短期免疫抑制性泼尼松龙治疗可导致持续但可逆的肾高滤过状态。电解质变量的改变会影响此类患者血液检查的临床解读。
